Hepatocellular carcinoma and bilary tract cancer receive first line chemotherapy HCC BTC EPC
Conditions
Interventions
Participants in the control group will receive standard clinical care from a medical oncologist according to institutional and international guidelines (such as NCCN Guidelines), which includes standa
s discretion. While this group will not receive proactive, integrated palliative care or structured patient-reported outcome assessments, the treating oncologist can still request a reactive palliativ
however, they will continu
Treatment,Treatment
Sponsors
Faculty of Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Participants aged 20 years or older who can communicate and understand the Thai language, and willingly provide written informed consent to participate in the study. 2) Diagnosed by histology or radiology with advanced, unresectable, or metastatic hepatocellular carcinoma (HCC) (such as BCLC stage C, or stage B unsuitable for loco-regional therapy), or diagnosed with advanced, unresectable, or metastatic biliary tract cancer (BTC), which includes intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and gallbladder cancer (GBC). 3)Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 4)Life expectancy of more than 3 months. 5)Planned to receive systemic cancer therapy as first-line treatment. 6) Able and willing to complete patient-reported outcome questionnaires throughout the study period.
Exclusion criteria
Exclusion criteria: 1) Participants who have previously received systemic cancer therapy, such as chemotherapy, targeted therapy, or immunotherapy, for advanced or metastatic cancer. 2) Participants who are already receiving care from a palliative care service. 3)Participants with severe or complex comorbidities, such as severe psychiatric disorders, which the investigator deems may hinder protocol adherence or impact the participant's safety and outcome assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life week 4 8 and 12 after enroll FACT-Hep score | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom Burden week 12 after enroll ESAS-r ,Emotional Status week 12 after enroll PHQ-9 ,Overall Survival week 12 after enroll or dead Rate of survival ,Caregiver Satisfaction week 12 after enroll FAMCARE-2 | — |
Countries
Thailand
Contacts
Public ContactSuebsakool Thammakhan
Faculty of Medicine, Chiang Mai University
Outcome results
None listed